Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

kandy therapeutics allergan acquisition

News and Trends 26 Jan 2018

New British Spinout May Get Snapped Up by Allergan for $400M

KaNDy Therapeutics, a women’s health spinout helmed by Mary Kerr, is rumored to be in acquisition talks that value the company at $400M (€322M). Details are sparse, but according to a report from Bloomberg, Stevenage-based KaNDy Therapeutics is supposedly in the late stages of a discussion with Allergan about a possible buyout. KaNDy, a recent spinout […]

January 26, 2018 - 1 minutemin - By Evelyn Warner

Pixium Vision bionic implant PRIMA

News and Trends 26 Jan 2018

Update: Bionic Implant Restores Vision in a Human for the First Time

Update (26/01/2018): A first patient was implanted with Pixium Vision’s PRIMA bionic device. A month after implantation, the device was activated and the patient, who suffered from severe vision loss due to age-related macular degeneration (AMD), reported “a first perception of light from the central zone where there was none previously,” according to principal investigator Dr. […]

January 26, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

acesion pharma cardiac arrhythmia 1

Startup Scout 26 Jan 2018

This Danish Biotech is Working on Better, Safer Drugs for Cardiac Arrhythmia

This week, we’re visiting Acesion Pharma in Copenhagen, a biotech that is developing more effective, safer drugs for atrial fibrillation, the most common form of cardiac arrhythmia. Mission: Since being founded in 2011, Acesion has already caught our attention, being named as one of our top biotechs in Copenhagen. The biotech focuses on the development of […]

January 26, 2018 - 2 minutesmins - By Alex Dale

epilepsy cannabinoid drug gw pharma 1

News and Trends 25 Jan 2018

Yet More Good News for GW Pharma’s Cannabinoid Drug Against Epilepsy

New data in The Lancet provides further support for GW Pharma’s drug, Epidiolex, for the treatment of a rare form of epilepsy. GW Pharmaceuticals has achieved encouraging Phase III results for Epidiolex, which have been published in leading scientific journal, The Lancet. The company’s lead candidate is being developed for the treatment of epilepsy – a […]

January 25, 2018 - 3 minutesmins - By Alex Dale

rexgenero cell therapy cli3 1

News and Trends 25 Jan 2018

British Biotech Treats First Phase III Patient in its Critical Limb Ischemia Trial

Rexgenero has treated the first patient in a Phase III trial investigating REX-001, the biotech’s cell therapy for critical limb ischemia. Rexgenero is a biotech working on regenerative medicine techniques to treat critical limb ischemia (CLI). The condition is characterized by blocked arteries in the lower limbs that can force doctors to amputate. The company has […]

January 25, 2018 - 3 minutesmins - By Alex Dale

luxturna rights novartis deal1

News and Trends 25 Jan 2018

Novartis Will Bring US Gene Therapy for Blindness to Europe

The Swiss pharma has bought into the gene editing therapy game in a deal with Spark worth $170M (€137M) for commercialization rights outside the US. Novartis first marked out its position as a gene therapy leader in 2012 when it threw its hat into the CAR-T ring. Just a few months after the FDA approved […]

January 25, 2018 - 2 minutesmins - By Evelyn Warner

ADVERTISEMENT

contact lens glucose diabetes

In Depth 25 Jan 2018

What Happened to the Plans for a Smart Contact Lens for Diabetics?

Originally projected to be on the market by 2020, excitement about the contact lens to measure glucose levels from Novartis and Google has waned. Why? In 2016, smart wearables growth was steady but a recent study predicts that the market will pick up this year introducing innovative products to the consumer market: according to CCS Insight, the market for […]

January 25, 2018 - 5 minutesmins - By External Contributor

pancreatic cancer flu virus treatment 1

News and Trends 25 Jan 2018

Researchers Take Aim at Pancreatic Cancer with a Modified Flu Virus

In an early study at Queen Mary University in London, a modified flu virus has been able to block the growth of pancreatic cancer. For the first time, researchers at Queen Mary University, London, have shown that pancreatic cancer can be targeted using a modified flu virus. During a study, published in Molecular Cancer Therapeutics, […]

January 25, 2018 - 3 minutesmins - By Alex Dale

retinitis pigmentosa treatment chip 1

News and Trends 24 Jan 2018

New Retinitis Pigmentosa Treatments? This Blood-Retina Chip Could Help!

A new ‘organ-on-a-chip’ device for the blood-retina barrier could speed up the development of treatments for eye diseases like retinitis pigmentosa. Researchers from Microelectronics Institute of Barcelona, Vall d’Hebron Research Institute, and Universitat Autònoma de Barcelona have developed a microfluidic chip that mimics the human blood-retinal barrier in the eye. The study, published in Lab on a […]

January 24, 2018 - 3 minutesmins - By Alex Dale

antibiotic resistance pharma efforts 1

News and Trends 24 Jan 2018

Biotech and Pharma Boost R&D and Slow Sales to Beat Antibiotic Resistance

To fight antibiotic resistance, the independent report found that companies are developing new drugs, discouraging their overselling, limiting their run-off into wastewater, and tracking the spread of superbugs. Antibiotics are becoming ineffective at an alarming rate due to our misuse in healthcare, animals, and crops. Antibiotic resistance is responsible for 700,000 deaths each year, which is expected to continue […]

January 24, 2018 - 3 minutesmins - By Alex Dale

breast cancer stop metastasis 1

News and Trends 24 Jan 2018

No Entry! This Protein Could Stop Breast Cancer from Escaping to the Rest of the Body

Spanish scientists have found genes that maintain breast cancer cells in a dormant state, which could be manipulated to control the spread of the disease. The time taken for breast cancer to spread varies among patients and not much is known about the mechanisms that control it. Researchers at the Institute for Research in Biomedicine […]

January 24, 2018 - 3 minutesmins - By Alex Dale

genfit nash pediatric trial 1

News and Trends 23 Jan 2018

NASH Leader goes Pediatric with Clinical Trial Launch in US

The FDA has cleared Genfit to kick off clinical trials to see if its NASH drug, elafibranor, can also help children. Genfit develops diagnostic and therapeutic tools for metabolic and inflammatory diseases, particularly those affecting the liver. Its lead candidate, elafibranor, targets Non-Alcoholic Stato-Hepatitis (NASH), and the company’s plan to begin testing it in children has been supported […]

January 23, 2018 - 2 minutesmins - By Alex Dale

ADVERTISEMENT